630-580-1088 sales@ambeed.com
Structure Search

List Search MOL Search Structure Search

0
Chemistry
Asymmetric Synthesis >>Chiral Building BlocksChiral Catalysts, Chiral Ligands and Chiral ReagentsChiral Resolution ReagentsCatalysis Chemistry >>Achiral Crown LigandsC-H ActivationCarbon-Donor LigandsChiral Crown LigandsCross-CouplingCross-Coupling Using Transition Metal CatalystsDACH or Trost LigandsDiketone LigandsHydrogenationChemical Biology >>Conjugation ChemistryGlycoscienceLinkers and CrosslinkersNucleic Acid ChemistryPEGylation
Peptide ChemistryPhotolabile Protecting GroupHeterocyclic Building Blocks >>AcridinesAliphatic HeterocyclesAromatic HeterocyclesAzetidinesBenzimidazolesBenzisoxazolesBenzodioxansBenzofuransBenzothiazolesInorganic reagents >>Inorganic reagentOrganic Building Blocks >>Acyl ChloridesAlcoholsAldehydesAliphatic Chain HydrocarbonsAliphatic Cyclic Hydrocarbons
AlkenylsAlkylsAlkynylsAmidesOrganometallic Reagents >>Grignard ReagentsOrganoarsenicOrganobismuthOrganoboronOrganogermaniumOrganolithiumOrganomercuryOrganosiliconOrganotinSpecialty Synthesis >>Enzyme-Mediated SynthesisFluorous SynthesisIonic LiquidsSolid Supported SynthesisStains and Dyes >>
Acid DyesAzoic DyesBasic DyesDirect DyesDisperse DyesDye IntermediatesMordant DyesOil DyesOther Stains and DyesSynthetic Reagents >>Acids and BasesC-C Bond FormationC-X Bond Formation (Halogen)C-X Bond Formation (Non-Halogen)Chelation and Complexation CompoundsCondensation AgentsCouplingDehydrating ReagentsFluorination Reagent
Pharmaceutical Intermediates
Analgesics >>BenzhydrocodoneBicifadineCapsaicinCelecoxibDebio-0827DexamethasoneElagolix SodiumEsketamine HydrochlorideIbuprofen sodiumAnesthetics >>CiprofolEsketamine HydrochlorideFospropofol Fospropofol DisodiumLevobupivacaine RemimazolamRemimazolam BesilateRemimazolam besylateRopivacaineAnti-Addiction Agents >>Kakonein
Lofexidine HydrochlorideVarenicline Anti-inflammatory Agents >>ApremilastAsunaprevirATB-346 RelatedBalsalazide BaricitinibBencycloquidium BromideBudesonideCefiderocol Sulfate TosylateCeftaroline Fosamil AcetateAntibacterials >>AFN-1252 RelatedAlatrofloxacin Bedaquiline FumarateBesifloxacin BrilacidinCaspofungin AcetateCefiderocol Sulfate TosylateCefilavancinCeftaroline Fosamil
Anticonvulsants >>BrivaracetamCannabidiolEscitalopram OxalateEslicarbazepine Acetate RelatedFosphenytoinGabapentin EnacarbilJNJ-10234094LacosamideLevetiracetam RelatedAntidementia Agents >>Azeliragon RelatedDavunetideDonepezil HydrochlorideDonepezil RelatedEnsaculinFlorbetaben Flortaucipir F 18Flutemetamol IdalopirdineAntidepressants >>4-Chlorokynurenine
AgomelatineAgomelatine RelatedAllopregnanolone RelatedAmibegronAmitifadineAripiprazole RelatedBasimglurantBefloxatoneAntiemetics >>AprepitantAprepitant RelatedDolasetron RelatedDolasetron Mesylate HydrateFosaprepitant DimeglumineFosaprepitant RelatedOlanzapinePalonosetron RelatedPalonosetron HydrochlorideAntifungals >>Anidulafungin RelatedCabotegravirMore >>
Inhibitors/Agonists
ADC >>ADC LinkerADC Linker with PayloadADC ToxinAnti-infection >>3CLproAntibacterialAntifungalAntiparasiticAntiprotozoalAntiviralBVDVCMVDengue VirusApoptosis >>Apoptosis InducerBcl-2c-Mycc-RETC/EBPCARDCaspase
DAPKIAPAutophagy >>AutophagyLC3LRRK2LysosomemitoNEETPPTSPHKTFEBULKBiochemical Reagent >>Cationic & Neutral LipidsDendrimersDye ReagentIntermediate and OthersCell Cycle >>APCAurora KinaseBUBCasein Kinase
Cdc25CDKChkCRM1DHFRCytoskeleton >>ActinArp2/3 ComplexCytoplasmic dyneinDynaminFAKFilamin-AGap JunctionIntegrinMicrotubule/TubulinDNA Damage >>AP endonucleaseATAD5ATM/ATRBRCADNA Alkylator/CrosslinkerMore >>
Material Science
Aggregation-Induced Emission >>Other AIE BlocksTetraphenylethylene SeriesElectronic Materials >>Battery MaterialsDye-Sensitized Solar Cell (DSSC) MaterialsElectronic MaterialLiquid Crystal (LC) MaterialsMolecular ConductorsOrganic Light-Emitting Diode (OLED) MaterialsOrganic Solar Cell (OPV) MaterialsOrganic Transistor (OFET) MaterialsPerovskite Solar Cell (PSC) MaterialsMagnetic Materials >>Magnetic Ionic LiquidsMagnetic MaterialMagnetic Metal Complexes Organic Radicals Material Chemical Compounds >>Ligands for Functional Metal ComplexesLiquid Crystal (LC) Building BlocksPhthalocyanine Building BlocksPolymer and Macromolecule Semiconductor Building BlocksSmall Molecule Semiconductor Building BlocksSolubility Enhancing Reagents Supramolecular Host Materials MOF Ligands >>
Carboxylic MOF ligandsMOF ligands of nitrogenous carboxylic acidsNitrogen containing MOF ligandsOther MOF ligandsNanomaterials >>Carbon NanomaterialsCeramic MembranesDendrimersGold NanoparticlesIron Oxide NanoparticlesMaterials by ApplicationMesoporous MaterialsMetals and Metal AlloysNano Minerals: NanoclaysOLED Materials >>DopantHostHTMOLED IntermediatesOther OLED related materialsOLED Materials >>DopantHostHTMOther OLED related metarialsOptical Materials >>Coumarin Dyes
Cyanine and Squarylium DyesDCM DyesDipyrromethene DyesFluorescence MaterialsFluorescent ProbesHeat and Pressure Sensitive DyesNear-Infrared (NIR) DyesOrganic Non-Linear Optical (NLO) MaterialsOrganic monomer of COF >>Aldehyde based COF monomerAlkynyl COF monomerAmino COF monomerBoric acid COF monomerCyano COF monomerMultifunctional COF monomerOther COF monomerTriphene seriesOrganic Pigments >>Organic PigmentOther Materials >>Mateial OtherPolymer Science >>MonomersPolymer AdditivesPolymerization ReagentsPolymersResins
Life Science
ADC-linkers >>ADC-linkerAmino Acids >>Amino AcidAmino Acid DerivativesAnalytical Science >>Stable IsotopesAPIs >>API
DNA/RNA >>Nucleosides and NucleotidesEnzymes >>EnzymeOther Life Science >>CRISPR/Cas9eIFIRE1Neuronal Signaling
Sigma ReceptorPeptides >>PeptideStandard Substrates >>Standard SubstrateSteroids >>Other Steroids
Contact Us
Home Cart 0 Sign in  
X
Chemistry
Heterocyclic Building Blocks
Pyridines
1-(5-Chloro-2-pyridyl)piperazine
Chemistry
Heterocyclic Building Blocks
Organic Building Blocks
Pyridines
Piperazines Chlorides

[ CAS No. 87394-65-8 ]

{[proInfo.proName]} ,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 87394-65-8
Chemical Structure| 87394-65-8
Chemical Structure| 87394-65-8
Structure of 87394-65-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 87394-65-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 87394-65-8 ]

SDS Specification
Alternatived Products of [ 87394-65-8 ]

Product Details of [ 87394-65-8 ]

CAS No. :87394-65-8 MDL No. :MFCD04115049
Formula : C9H12ClN3 Boiling Point : -
Linear Structure Formula :- InChI Key :ZTLOZFLZBKZABP-UHFFFAOYSA-N
M.W :197.66 Pubchem ID :3805301
Synonyms :

Calculated chemistry of [ 87394-65-8 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.44
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 60.61
TPSA : 28.16 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.53 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.05
Log Po/w (XLOGP3) : 1.37
Log Po/w (WLOGP) : 0.38
Log Po/w (MLOGP) : 1.23
Log Po/w (SILICOS-IT) : 1.77
Consensus Log Po/w : 1.36

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.2
Solubility : 1.24 mg/ml ; 0.00625 mol/l
Class : Soluble
Log S (Ali) : -1.56
Solubility : 5.39 mg/ml ; 0.0273 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.14
Solubility : 0.143 mg/ml ; 0.000721 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.02

Safety of [ 87394-65-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H317-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 87394-65-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 87394-65-8 ]

[ 87394-65-8 ] Synthesis Path-Downstream   1~40

  • 1
  • [ 110-85-0 ]
  • [ 16110-09-1 ]
  • [ 87394-65-8 ]
YieldReaction ConditionsOperation in experiment
92% In dichloromethane; EXAMPLE 10 3-(4-[5-Chloro-2-pyridyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine A mixture of 2,5-dichloropyridine (10.0 g, 67.6 mmol) and piperazine (58.1 g, 675 mmol) was stirred at 165 C. for 2 h. The mixture was allowed to cool, slurried with dichloromethane (200 ml) and the solid collected by filtration. The filtrate was concentrated in vacuo and the procedure repeated. The residue after concentration of the filtrate was purified by flash chromatography twice (eluding with 1% ammonia, 10% methanol in dichloromethane) to give 1-(5-chloro-2-pyridyl)piperazine (12.25 g, 92%) as a tan solid.
78% In 1,2-dimethoxyethane; at 150℃; for 12h; A one to one mixture of piperazine and 2, 5-dichloropyridine inethylene glycol was heated at 150C for 12 hrs. After cooling to roomtemperature, the mixture was diluted with EtOAc (200 mL) followed by washing with saturated NaHCO3 (2×200 mL). The organic layer wasdried over Na2SO4, and filtered. The filtrate was concentrated in vacuoto dryness to obtain a residue that was purified by column chromatographyon silica gel to afford 1-(5-chloropyridin-2-yl)piperazine as anoily residue in a yield of 78%.1H NMR (300 MHz, CDCl3): delta 8.10 (1H, d, J=6.0 Hz), 7.41 (1H, dd,J=6.0, 9.0 Hz), 6.57 (1H, d, J=9.0 Hz), 3.46-3.49 (4H, m),2.96-3.00 (4H, m), 2.67 (1H, brs).13C (75 MHz, CDCl3): delta 157.6, 146.3, 137.1, 120.4, 107.8, 45.3,44.8.
In ISOPROPYLAMIDE; ethyl acetate; 5-Chloro-2-piperazinopyridine 2,5-Dichloropyridine (148 g, 1.0M) was dissolved in anhydrous dimethylacetamide (1000 ml) and anhydrous piperazine (258 g, 3.0M) was added. Stirred at 120 C. for 4 hours. Cooled and evaporated under hi-vac on cold-finger buchi. The residue was stirred in ethyl acetate (3000 ml). Filtered of the solid, washing with ethyl acetate (500 ml) The combined ethyl acetate filtrates were washed with H2O, dried over MgSO4, filtered and evaporated to yield a yellow solid. Yield 1 82.5 g. NMR (CDCl3) d 8.1, d 1H; 7.4 dd 1H; 6.6, d 1H; 3.5, m 4H; 3.0, m 1H; MS found MH+ 198
(1) 1-(5-Chloropyridin-2-yl)piperazine To piperazine (29.0 g) dissolved at 115 C. was added 2,5-dichloropyridine (5.1 g) and the mixture was stirred at 140-150 C. for 1 hr. The reaction mixture was poured into a 1N aqueous sodium hydroxide solution and extracted with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated to give the title compound (5.0 g) as a pale-brown solid. 1H-NMR(DMSO-d6)delta: 2.76(4H, t, J=5.3 Hz), 3.38(4H, t, J=5.3 Hz), 6.81(1H, d, J=8.6 Hz), 7.56(1H, dd, J=3.3, 8.6 Hz), 8.09(1H, d, J=2.6 Hz); MS(EI): 197(M+).

Reference： [1]Patent: US5432177,1995,A
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1857 - 1872
[3]Bioorganic and Medicinal Chemistry,2019,vol. 27,p. 2421 - 2426
[4]Chemical and Pharmaceutical Bulletin,1991,vol. 39,p. 2288 - 2300
[5]Patent: US2003/139419,2003,A1
[6]Patent: US6455528,2002,B1
  • 2
  • [ 110-85-0 ]
  • [ 87412-10-0 ]
  • [ 87394-65-8 ]
Reference： [1]Journal of Medicinal Chemistry,1983,vol. 26,p. 1696 - 1701
  • 3
  • [ 87394-65-8 ]
  • [ 99095-09-7 ]
  • [ 106708-44-5 ]
Reference： [1]Chemical and Pharmaceutical Bulletin,1991,vol. 39,p. 2288 - 2300
  • 4
  • [ 87394-65-8 ]
  • (4,5-dihydro-1H-benzo[g]indazol-3-ylmethyl)-trimethylammonium iodide [ No CAS ]
  • 3-[4-(5-chloropyridin-2-yl)piperazin-1-ylmethyl]-4,5-dihydro-1H-benzo[g]indazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
21% With N-ethyl-N,N-diisopropylamine; In dichloromethane; N,N-dimethyl-formamide; EXAMPLE 2 3-(4-(5-Chloropyridin-2-yl)-piperazin-1-ylmethyl)-4,5-dihydro-1H-benzo[g]indazole A solution of (4,5-dihydro-1H-benzo[g]indazol-3-ylmethyl)-trimethylammonium iodide (0.40 g), <strong>[87394-65-8]1-(5-chloropyridin-2-yl)-piperazine</strong> (0.32 g) and diisopropylethylamine (0.28 cm3) in DMF (10 cm3) was heated under argon at 100 C. for 24 hours. The mixture was cooled, poured into water (25 cm3) and extracted with 10% methanol-dichloromethane (3*15 cm3). The extracts were concentrated and the residual oil was partitioned between water (20 cm3) and 50% ethyl acetate-diethyl ether (20 cm3) to wash away DMF. The organic layer was dried (MgSO4), filtered and concentrated to give a brown solid. Flash column chromatography on silica gel, eluding with 5% methanol-dichloromethane, gave the coupled product as a white solid, which was recystallised from dichloromethane to give the title compound (0.087 g; 21%) as white crystals, m.p. 207-208 C. (from CH2 Cl2); Found: C, 66.3; H, 5.8; N, 18.1.
Reference： [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 1731 - 1743
[2]Patent: US5686480,1997,A
  • 5
  • [ 515160-77-7 ]
  • [ 87394-65-8 ]
  • 3-{2-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-ethyl}-8-furan-2-yl-3<i>H</i>-[1,2,4]triazolo[5,1-<i>i</i>]purin-5-ylamine [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 1659 - 1662
  • 6
  • [ 401564-36-1 ]
  • [ 87394-65-8 ]
  • [ 401566-32-3 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 2618 - 2621
  • 7
  • [ 4214-79-3 ]
  • 3.5-dichloro-2-oxy-pyridine [ No CAS ]
  • [ 87394-65-8 ]
Reference： [1]Journal of Medicinal Chemistry,1983,vol. 26,p. 1696 - 1701
  • 8
  • E-4-(2-bromo-2-methyl-propionylamino)-adamantane-1-carboxylic acid methyl ester [ No CAS ]
  • [ 87394-65-8 ]
  • E-4-{2-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-2-methyl-propionylamino}-adamantane-1-carboxylic acid methyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydroxide;tetrabutylammomium bromide; In dichloromethane; water; at 20℃; for 20h; A two phase suspension of E-4-(2-bromo-2-methyl-propionylamino)-adamantane-1-carboxylic acid methyl ester (36 mg, 0.1 mmol) from Example 34B, 1-(5-chloro-2-pyridyl)piperazine (20 mg, 0.11 mmol) and tetrabutylammonium bromide (3 mg, 0.01 mmol) in DCM (0.2 mL) and 50% NaOH (0.2 mL) was stirred at room temperature for 20 hours. After that the reaction mixture was diluted with water and DCM and layers separated. Organic layer was washed with water (2*2 mL), dried (MgSO4) and filtered. The filtrate was concentrated under reduced pressure to provide crude methyl ester of the title compound that was purified on reverse phase HPLC and hydrolyzed with 3N HCL at 60 C. over 6 hours. Drying of the reaction mixture under reduced pressure provided the title compound as a white solid (35 mg, 75%). 1H NMR (400 MHz, Py-d5) delta 8.38 (s, 1H), 7.87 (d, J=7.8 Hz, 1H), 6.8 (d, J=9 Hz, 1H), 4.31 (d, J=8.1 Hz, 1H), 3.64 (s, 4H), 2.59 (s, 4H), 2.25 (m, 4H), 2.17 (s, 2H), 2.11 (s, 2H), 1.96 (s, 1H), 1.87 (d, J=14.4 Hz, 2H), 1.62 (d, J=12.8 Hz, 2H), 1.31 (s, 6H); MS (ESI+) m/z 461 (M+H)+.
Reference： [1]Patent: US2005/245534,2005,A1 .Location in patent: Page/Page column 47
  • 9
  • methyl (E)-4-(2-bromo-2-methyl-propionylamino)-adamantane-1-carboxylate [ No CAS ]
  • [ 87394-65-8 ]
  • (E)-4-{2-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-2-methyl-propionylamino}-adamantane-1-carboxylic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
A two phase suspension of methyl (E)-4-(2-bromo-2-methyl-propionylamino)-adamantane-1-carboxylate (36 mg, 0.1 mmol) from Example 34B, 1-(5-chloro-2-pyridyl)piperazine (20 mg, 0.11 mmol) and tetrabutylammonium bromide (3 mg, 0.01 mmol) in DCM (0.2 mL) and 50% NaOH (0.2 mL) was stirred at room temperature for 20 hours. After that the reaction mixture was diluted with water and DCM and layers separated. Organic layer was washed with water (2*2 mL), dried (MgSO4) and filtered. The filtrate was concentrated under reduced pressure to provide crude methyl ester of the title compound that was purified on reverse phase HPLC and hydrolyzed with 3N HCL at 60 C. over 6 hours. Drying of the reaction mixture under reduced pressure provided the title compound as a white solid. 1H NMR (400 MHz, Py-d5) delta 8.38 (s, 1H), 7.87 (d, J=7.8 Hz, 1H), 6.8 (d, J=9 Hz, 1H), 4.31 (d, J=8.1 Hz, 1H), 3.64 (s, 4H), 2.59 (s, 4H), 2.25 (m, 4H), 2.17 (s, 2H), 2.11 (s, 2H), 1.96 (s, 1H), 1.87 (d, J=14.4 Hz, 2H), 1.62 (d, J=12.8 Hz, 2H), 1.31 (s, 6H); MS(ESI+) m/z 461 (M+H)+.
Reference： [1]Patent: US2005/277647,2005,A1 .Location in patent: Page/Page column 35
  • 10
  • [ 87394-65-8 ]
  • [ 223512-41-2 ]
  • [ 223512-06-9 ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate; In N-methyl-acetamide; (2) N-(4-((4-(5-Chloropyridin-2-yl)piperazin-1-yl)methyl)phenylmethyl)acetamide A solution of N-(4-chloromethylphenylmethyl)acetamide (1.5 g), <strong>[87394-65-8]1-(5-chloropyridin-2-yl)piperazine</strong> (1.5 g) and potassium carbonate (1.6 g) in dimethylformamide (20 ml) was stirred at 70-80 C. for 8.5 hr. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated to give a brown solid (3.1 g). The obtained brown solid was crystallized ethyl acetate to give the title compound (1.3 g) as pale-yellow crystals, m.p.=155-156 C.; 1H-NMR(DMSO-d6)delta: 1.87(3H, s), 2.35-2.45(4H, m), 3.45-3.50(6H, m), 4.23(2H, d, J=5.9 Hz), 6.84(1H, d, J=9.2 Hz), 7.19-7.29(4H, m), 7.58(1H, dd, J=2.6, 9.2 Hz), 8.09(1H, d, J=2.6 Hz), 8.31(1H, t, J=5.3 Hz); IR(KBr): 3313, 2915, 2815, 1645, 1591 cm-1; MS(EI): 358(M+); Elemental analysis: Calculated: C; 63.59, H; 6.45, N; 15.61; Found: C; 63.55, H; 6.48, N; 15.48.
Reference： [1]Patent: US6455528,2002,B1
YieldReaction ConditionsOperation in experiment
Step 1. 1-(5-Chloropyridin-2-yl)piperazine. Refer to Chart C Following the general procedure of Example 33, Step 1, and making non-critical variations, 2,5-dichloropyridine (Aldrich; 5.10 g), piperazine (14.8 g), water (50 mL), and N,N-dimethylacetamide (2 mL) give 3.42 g of 1-(5-chloropyridin-2-yl)piperazine; mp 92-107 C.; IR 1480, 1244, 1390, 1589 815 cm-1; 1 H NMR (CDCl3) delta2.98, 3.47, 6.58, 7.42, 8.11.
1-(5-Chloro-2-pyridyl)piperazine, M.P., 59-61 C.;
  • 12
  • [ 87394-65-8 ]
  • 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]-methyl]imidazo[1,2-a]pyridine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In ethylene glycol; Step 2. 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]methyl]imidazo[1,2-a]pyridine Following the general procedure of Example 33, Step 2, and making non-critical variations, <strong>[87394-65-8]1-(5-chloropyridin-2-yl)piperazine</strong> (0.424 g), 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (Example 4, Step 1; 0.517 g), triethylamine (0.282 g), and ethylene glycol (2 mL) give, after crystallization from dichloromethane/ethyl ether, 0.621 g of the title compound; mp 137-138 C.; MS m/z 361, 363; IR 1593, 1480, 1245, 1324, 801, 1304 cm-1; 1 H NMR (CDCl3) delta2.67, 3.55, 3.75, 6.57, 7.13, 7.41, 7.52, 7.53, 8.10, 8.14.
Reference： [1]Patent: US5912246,1999,A
  • 13
  • [ 99585-36-1 ]
  • [ 87394-65-8 ]
  • [ 958873-02-4 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 5940 - 5943
  • 14
  • [ 1088886-69-4 ]
  • [ 87394-65-8 ]
  • [ 1088886-40-1 ]
YieldReaction ConditionsOperation in experiment
46% With triethylamine; In acetonitrile; at 80℃; for 15h; Example 5; N-(2-f 1 H- 1 ,2,3 -triazol-4-vDpropan-2- yl>4-(5 -chloropyridin-2- vPpiperazine- 1 -sulfonamide[00102] l-(5-Chloropyridin-2-yl)piperazine (61.0 mg, 0.309 mmol) and N-(2-(lH-1, 2,3 -triazol-4-yl)propan-2-yl)-2-oxooxazolidine-3 -sulfonamide (85.0 mg, 0.309 mmol) were dissolved in acetonitrile (2 mL). Triethylamine (0.861 mL, 0.618 mmol) was added to this solution, and the reaction mixture was heated to a temperature of 800C for 15 hours. After purification by silica chromatography using a gradient of 25%-66% EtOAc/hexanes, N-(2- ( IH-1, 2,3 -triazol-4-yl)propan-2-yl)-<strong>[87394-65-8]4-(5-chloropyridin-2-yl)piperazine</strong>-l -sulfonamide (54.4 mg, 46%) was isolated as a solid. MS APCI (-) m/z 383.9 detected. 1H NMR (400 MHz. CD3OD) delta 8.01 (s, IH), 7.75 (s, IH), 7.74-7.50 (m, IH), 6.73-6.78 (m, IH), 3.38 (m, 4H), 3.04 (m, 4H), 1.69 (s, 6H).
Reference： [1]Patent: WO2008/147763,2008,A1 .Location in patent: Page/Page column 23
  • 15
  • [ 1219623-42-3 ]
  • [ 87394-65-8 ]
  • [ 1219624-30-2 ]
YieldReaction ConditionsOperation in experiment
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; Example 53; l-{2-[4-(5-chloropyridin-2-yl)piperazin-l-yl]-2-oxoethyl}-3,3-diphenylpyrrolidin-2-one; A solution of l-(5-chloropyridin-2-yl)piperazine (0.037 g, 0.186 mmol), 2-(2-oxo-3,3- diphenylpyrrolidin-l-yl)acetic acid (Example 1C, 0.050 g, 0.169 mmol) and iV1-((ethylimino)methylene)-Lambdaf ,I -dimethylpropane- 1,3 -diamine hydrochloride (0.049 g, 0.254 mmol) in dichloromethane (2 mL) was stirred at room temperature. After stirring overnight, the reaction was loaded directly onto a SF 15- 12 silica gel column (Analogix, Burlington, WI), and the title compound was eluted using a gradient of 5% to 100% ethyl acetate/hexanes over 25 minutes (flow = 30 mL/minute). 1H NMR (300 MHz, CDCl3) delta ppm 8.12 (dd, J = 2.6, 0.7 Hz, 1 H), 7.45 (dd, J = 9.0, 2.7 Hz, 1 H), 7.18-7.38 (m, 10 H), 6.54 (dd, J = 9.1 , 0.7 Hz, 1 H), 4.24 (s, 2 H), 3.67-3.72 (m, 2 H), 3.54 (t, J= 6.6 Hz, 2 H), 3.51-3.56 (m, 2 H), 3.44-3.50 (m, 2 H), 3.36-3.42 (m, 2 H), 2.82 (t, J= 6.6 Hz, 2H); MS (ESI+) m/z 475 (M+H)+.
Reference： [1]Patent: WO2010/39947,2010,A1 .Location in patent: Page/Page column 90
  • 16
  • C21H29NO4 [ No CAS ]
  • [ 87394-65-8 ]
  • C30H39ClN4O3 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 1728 - 1734
  • 17
  • [ 1143575-87-4 ]
  • [ 87394-65-8 ]
  • [ 1143574-10-0 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 120℃;Microwave irradiation; 8.5 (1-{2-[4-(5-Chloropyridin-2-yl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5lambda4-thieno[3,2-d]pyrimidin-4-ylamino}-cyclopropyl)-methanol Example 13 0.1 g (IV-4) (see 8.4) is placed in 3 ml N-methyl-2-pyrrolidone, then 182 mul diisopropylethylamine and 0.08 g <strong>[87394-65-8]1-(5-chloropyridin-2-yl)-piperazine</strong> are added. The reaction mixture is heated in the microwave at 120 C., until no further reaction takes place. The product is purified by chromatography (preparative HPLC, method A). Analytical HPLC-MS (method B): RT=1.09 min.
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 120℃;Microwave irradiation; 8.5 (1-{2-[4-(5-chloropyridin-2-yl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5lambda4-thieno[3,2-d]pyrimidin-4-ylamino}-cyclopropyl)-methanol (Example 1.8) 0.1 g (IV-4) is placed in 3 ml N-methyl-2-pyrrolidone, then 182 mul diisopropylethylamine and 0.08 g <strong>[87394-65-8]1-(5-chloropyridin-2-yl)-piperazine</strong> are added. The reaction mixture is heated to 120 C. in the microwave until there is no further reaction. The product is purified by chromatography (preparative HPLC, method A). Analytical HPLC-MS (method B): RT=1.09 min.
Reference： [1]Patent: US2010/305102,2010,A1 .Location in patent: Page/Page column 16-17
[2]Patent: US2013/237527,2013,A1 .Location in patent: Paragraph 0232; 0233
  • 18
  • [ 107-14-2 ]
  • [ 87394-65-8 ]
  • [ 1252676-29-1 ]
Reference： [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 7344 - 7355
  • 19
  • 6-bromo-N-((E)-5-hydroxyadamantan-2-yl)picolinamide [ No CAS ]
  • [ 87394-65-8 ]
  • 6-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-N-((E)-5-hydroxyadamantan-2-yl)picolinamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
36% Step 3: Synthesis of 6-(4-(5-Chloropyridin-2-yl)piperazin-1-yl)- N -(( E )-5-hydroxyadamantan-2-yl)picolinamide [257] 6-Bromo-N-((E)-5-hydroxyadamantan-2-yl)picolinamide(50 mg, 0.142 mmol), <strong>[87394-65-8]1-(5-chloropyridin-2-yl)piperazine</strong> (34 mg, 0.171 mmol), Pd2(dba)3 (2.6 mg, 0.003 mmol), xantphos (4.9 mg, 0.009 mmol), and sodium-tert-butoxide (20 mg, 0.213 mmol) were suspended in toluene (3 ml), and then the resulting liquid was stirred at 100oC under nitrogen stream for 3 hours. A saturated aqueous ammonium chloride solution (15 ml) was added to the resulting reaction liquid, followed by extraction with MC (20 ml x 2). The organic layer was dried over anhydrous sodium sulfate, followed by filtration and concentration, and then the residue thus obtained was subjected to MPLC (5% MeOH/MC), to obtain 24 mg of yellow solid (36%). MS (ESI): 468[M+H]+ [258]
Reference： [1]Patent: WO2011/139107,2011,A2 .Location in patent: Page/Page column 39-40
  • 20
  • [ 945422-86-6 ]
  • [ 87394-65-8 ]
YieldReaction ConditionsOperation in experiment
99% Step 2: Synthesis of 1-(5-Chloropyridin-2-yl)piperazine [255] Tert-butyl 4-(5-chloropyridin-2-yl)piperazine-1-carboxylate (170 mg, 0.571 mmol) was dissolved in MC (3 ml), followed by addition of trifluoroacetic acid (3 ml), and then the resulting mixture was stirred at room temperature for 2 hours. The resulting reaction liquid was concentrated under reduced pressure, followed by addition of a saturated aqueous NaHCO3 solution (15 ml), and extracted with MC (15 ml x 3). The organic layer was dried over anhydrous sodium sulfate, followed by filtration, concentration, and vacuum drying, to obtain 112 mg of white solid (99%).
Reference： [1]Patent: WO2011/139107,2011,A2 .Location in patent: Page/Page column 39
  • 21
  • [ 40473-01-6 ]
  • [ 87394-65-8 ]
Reference： [1]Patent: WO2011/139107,2011,A2
  • 22
  • [ 1590439-70-5 ]
  • [ 87394-65-8 ]
  • C30H33ClN6O7 [ No CAS ]
Reference： [1]ACS Combinatorial Science,2014,vol. 16,p. 232 - 237
  • 23
  • [ 87394-65-8 ]
  • [ 68691-77-0 ]
  • C21H24ClN5O6 [ No CAS ]
Reference： [1]ACS Combinatorial Science,2014,vol. 16,p. 232 - 237
  • 24
  • 2',3'-o-isopropylideneadenosine-5-carboxylic acid [ No CAS ]
  • [ 87394-65-8 ]
  • C22H25ClN8O4 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In acetonitrile; at 20℃; for 3h;Automated synthesizer; General procedure: Approximately 0.5 mmol of 2 and 0.5 mmol of HATU were dispensed in 24 reaction wells (MiniBlock XT) using a dispensing spatula and funnel. To each well were added 10 mL of anhydrous MeCN, (0.5 mmol) of the appropriate amine in MeCN, and then 0.13 mL of DIPEA (0.75 mmol) through the septa sheet. The reaction block was covered and shaken at room temperature for 180 minutes (TLC monitored). Two grams of silica gel were added to each well and the reaction block was placed on a parallel centrifugal evaporator. After automated flash chromatography, the obtained pure intermediate (0.25 mmol) and 4 mL of formic acid (50%) were dispensed in 24 reaction wells (MiniBlock XT), heated to 70 C and shaken vigorously for 2 h whereupon TLC showed no remaining starting material. Silica gel (1 g) was added to each well and the mixture was evaporated, dried on a parallel centrifugal evaporator and the dry solid was chromatographed to give the desired product.
Reference： [1]Nucleosides, nucleotides and nucleic acids,2014,vol. 33,p. 709 - 729
  • 25
  • 2-(1-oxo-2-oxaspiro[4.5]decan-3-yl)ethyl 4-methylbenzenesulfonate [ No CAS ]
  • [ 87394-65-8 ]
  • 3-{2-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-ethyl}-2-oxa-spiro[4.5]decan-1-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
51% In tetrahydrofuran; at 60℃; for 48h; To a solution of 2-(i--oxo-2-oxaspiro[45]decan-3--yflethyi 4-rnethyibenzenesuifonate (.050g, 0.1 5mmol) in 4mL Tetrahydrofuran, 1 -(5-chloropyridin-2- yl)piperazine (.073g, 0.37mmol) was added and stirred at 60 C for 48 hours. The precipitate was filtered. The filtrate was concentrated to an oil under reduced pressure. The crude oil was purified by reverse phase flash chromatography using acetonitrle/H20/0. 1% formic acid as eluent (5% acetonitrile to 95% acetonitrile over a 15 minute gradient) to afforded 3- {2-[4-(5-Chloro-pyridin-2-yl)-piperazin- 1-yl]-ethyl}-2-oxa-spiro[4.5]decan-1-one (0.027g, 51%) as an off white solid. ?H NMR (400MHz, Chloroform-d) oe 8.12 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 9.0 Hz, J = 2.6 Hz, 1H), 6.59 (d, J = 9.0 Hz, 1H) 4.52(m, 1H), 3.53(pen, J = 5.6 Hz, J = 1.4 Hz , 4H) 2.57 (m, 4H), 2.54(m, 2H), 2.43(m, 1H), 1.86(m, 4H), 1.69 (m, 6H), 1.35(m, 3H). LC/MS M+1 378.2.
51% In tetrahydrofuran; at 60℃; for 48h; To a solution of 2-(1 -oxo-2-oxaspiro[4.5j clecan-3-yl)ethyi 4- rnethyibenzenesuifonate (0.050g, 0.15 mmol) in 4 mL Tetrahydrofuran, 1-(5-chloropyridin-2- yl)piperazine (0.073g, 0.37mmol) was added and the reaction mixture was stirred at 60 C for 48 hours. The precipitate was filtered. The filtrate was concentrated to an oil under reduced pressure. The cmde oil was purified by reverse phase flash chromatography using acetonitrile/H20/0.1% formic acid as eluent (5% acetonitrile to 95% acetonitrile over a 15 minute gradient) to afforded 3- {2-[4-(5-chloro-pyridin-2-yl)-piperazin- 1 -ylj -ethyl } -2-oxa- spiro[4.Sjdecan-1-one (0.027g, 51%) as an off white solid. ?H NMR (400MHz, chloroform-d) 3 8.12 (d, J= 2.4 Hz, 1H), 7.43 (dd, J= 9.0 Hz, J 2.6 Hz, 1H), 6.59 (d, J 9.0 Hz, 1H)4.52(m, 1H), 3.53(pen, J= 5.6 Hz, J= 1.4 Hz, 4H) 2.57 (m, 4H), 2.54(m, 2H), 2.43(m, 1H), 1.86(m, 4H), 1.69 (m, 6H), 1.35(m, 3H). LC/MS M+1 378.2.
Reference： [1]Patent: WO2016/40554,2016,A1 .Location in patent: Paragraph 0267
[2]Patent: WO2016/183150,2016,A1 .Location in patent: Paragraph 0456
  • 26
  • 5-[(3,4-dihydro-4-oxophthalazin-1-yl)methyl]-2,4-difluorobenzoic acid [ No CAS ]
  • [ 87394-65-8 ]
  • N-(5-chloropyridin-2-yl)-N'-{5-[(3,4-dihydro-4-oxophthalazin-1-yl)methyl]-2,4-difluorobenzoyl}piperazine [ No CAS ]
Reference： [1]Acta Pharmacologica Sinica,2017,vol. 38,p. 1521 - 1532
  • 27
  • C15H16Cl2F3NO2 [ No CAS ]
  • [ 87394-65-8 ]
  • 2-chloro-N-(3-(4-(5-chloropyridin-2-yl)piperazine-1-carbonyl)-5-(trifluoromethyl)phenyl)-Nisopentylacetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
43.9 mg With N-ethyl-N,N-diisopropylamine; In dichloromethane; General procedure: To a solution of S7 (502.3 mg, 1.4 mmol) in THF (10 mL) containing 10 muL DMF was added oxalylchloride (360.0 muL, 0.3 mmol) at room temperature. The solution was stirred for 2 h andconcentrated. The resulting acid chloride S8 (37.0 mg, 0.1 mmol) was reacted with thecorresponding amine (0.2 mmol) and N,N-Diisopropylethylamine (52.3 muL, 0.3 mmol) overnight.The solution was extracted with ethyl acetate (3 mL), washed with citric acid solution, saturatedNaHCO3, and concentrated. The residue was then purified by preparative TLC.
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2682 - 2687
  • 28
  • [ 87394-65-8 ]
  • [ 3874-54-2 ]
  • 4-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-1-(4-fluorophenyl)butan-1-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydrogencarbonate; potassium iodide; In isopropyl alcohol; for 12h;Inert atmosphere; Reflux; General procedure: General Procedure I: A mixture of 4-chloro-1-(4-fluorophenyl)butan-1-one (1.0 g, 5.0 mmol), 1-(5-chloropyridin-2-yl)-1,4-diazepane (1.2 g,5.7 mmol), KI (250 mg), NaHCO3 (1.0 g, 11.9 mmol) in iPrOH (10 mL)was heated to reflux under N2 for 12 h. After cooling to rt, the mixturewas diluted with EtOAc (500 mL) and washed with water (2×300 mL).The organic layer was dried over Na2SO4, filtered and the filtrate wasconcentrated in vacuo to dryness to obtain a residue which was purifiedby column chromatography on silica gel to afford 4-(4-(5-chloropyridin-2-yl)-1,4-diazepan-1-yl)-1-(4-fluoro-phenyl)butan-1-one 2 as a freebase.
Reference： [1]Bioorganic and Medicinal Chemistry,2019,vol. 27,p. 2421 - 2426
  • 29
  • [ 87394-65-8 ]
  • 4-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-1-(4-fluorophenyl)butan-1-one hydrochloride [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry,2019,vol. 27,p. 2421 - 2426
  • 30
  • [ 87394-65-8 ]
  • 1-(5-chloropyridin-2-yl)-4-(4-(4-fluorophenyl)butyl)piperazine hydrochloride [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry,2019,vol. 27,p. 2421 - 2426
  • 31
  • [ 54540-58-8 ]
  • [ 87394-65-8 ]
  • 1-(5-chloropyridin-2-yl)-4-(4-(4-fluorophenyl)butyl)piperazine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydrogencarbonate; potassium iodide; In isopropyl alcohol; for 12h;Inert atmosphere; Reflux; General procedure: General Procedure I: A mixture of 4-chloro-1-(4-fluorophenyl)butan-1-one (1.0 g, 5.0 mmol), 1-(5-chloropyridin-2-yl)-1,4-diazepane (1.2 g,5.7 mmol), KI (250 mg), NaHCO3 (1.0 g, 11.9 mmol) in iPrOH (10 mL)was heated to reflux under N2 for 12 h. After cooling to rt, the mixturewas diluted with EtOAc (500 mL) and washed with water (2×300 mL).The organic layer was dried over Na2SO4, filtered and the filtrate wasconcentrated in vacuo to dryness to obtain a residue which was purifiedby column chromatography on silica gel to afford 4-(4-(5-chloropyridin-2-yl)-1,4-diazepan-1-yl)-1-(4-fluoro-phenyl)butan-1-one 2 as a freebase.
Reference： [1]Bioorganic and Medicinal Chemistry,2019,vol. 27,p. 2421 - 2426
  • 32
  • [ 380346-54-3 ]
  • [ 87394-65-8 ]
  • 2-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-N-(3-ethylphenyl)acetamide [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 3722 - 3740
  • 33
  • [ 78205-18-2 ]
  • [ 87394-65-8 ]
  • 2-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-N-(pyridin-3-yl)acetamide [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 3722 - 3740
  • 34
  • [ 1196093-57-8 ]
  • [ 87394-65-8 ]
  • 2-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-N-(pyrimidin-5-yl)acetamide [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 3722 - 3740
  • 35
  • [ 32428-61-8 ]
  • [ 87394-65-8 ]
  • 2-(4-(5-chloropyridin-2-yl)piperazin-1-yl)-N-(m-tolyl)acetamide [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 3722 - 3740
  • 36
  • N-(5-(tert-butyldimethylsilyloxy)pyridin-2-yl)-2-oxooxazolidine-3-sulfonamide [ No CAS ]
  • [ 87394-65-8 ]
  • N-(5-(tert-butyldimethylsilyloxy)pyridin-2-yl)-4-(5-chloropyridin-2-yl)piperazine-1-sulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
72% With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 130℃; for 0.5h;Microwave irradiation; A solution of /V-(5-(z
Reference： [1]Patent: WO2019/140188,2019,A1 .Location in patent: Paragraph 078
  • 37
  • [ 32315-10-9 ]
  • 5-[(tert-butyldimethylsilyl)oxy]pyridin-2-amine [ No CAS ]
  • [ 87394-65-8 ]
  • 1-phenylpiperidin-4-yl N-[5-[(tert-butyldimethylsilyl)oxy]pyridin-2-yl]carbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
32% To a solution of triphosgene (300 mg) in CH2CI2 (5 mL) was added 1- phenylpiperidin-4-ol (352 mg, 1.99 mmol) over 3 hr, followed by the addition of a solution of 5-[(tert-butyldimethylsilyl)oxy]pyridin-2-amine (448 mg, 2.00 mmol, 1.00 eq) in pyridine (1 mL) over 16 hr. The resulting solution was stirred an additional 16 h at rt, then extracted with 2x30 mL of CH2CI2. The combined organic layers were concentrated under vacuum and purified with silica gel chromatography using CH2CI2 / MeOH (20: 1) to afford 270 mg (32%) of the title compound as an off-white solid. LC-MS: (ES, m/z) 428.
Reference： [1]Patent: WO2019/140188,2019,A1 .Location in patent: Paragraph 0638
  • 38
  • 5-[(tert-butyldimethylsilyl)oxy]pyridin-2-amine [ No CAS ]
  • [ 87394-65-8 ]
  • 1-phenylpiperidin-4-yl N-(5-hydroxypyridin-2-yl)carbamate [ No CAS ]
Reference： [1]Patent: WO2019/140188,2019,A1
  • 39
  • 4-fluorophenyl N-[5-[(tert-butyldimethylsilyl)oxy]pyridin-2-yl]carbamate [ No CAS ]
  • [ 87394-65-8 ]
  • N-[5-[(tert-butyldimethylsilyl)oxy]pyridin-2-yl]-4-(5-chloropyridin-2-yl)piperazine-1-carboxamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
86% With triethylamine; In dichloromethane; at 0 - 20℃; for 16h; A solution of Intermediate?A? (150 mg, 0.41 mmol, 1.00 equiv), and l-(5- chloropyridin-2-yl)piperazine (82 mg, 0.41 mmol, 1.00 equiv), and Et3N (126 mg, 1.25 mmol, 3.00 equiv) in CH2CI2 (5 mL) at 0 C was allowed to warm to rt with stirring for 16, then concentrated under vacuum and purified with silica gel chromatography using with EtOAc / hexane (1/2) to afford 160 mg (86%) of the title compound as an off-white solid. LC-MS: (ES, m/z): 448.
Reference： [1]Patent: WO2019/140188,2019,A1 .Location in patent: Paragraph 0529
  • 40
  • [ 87394-65-8 ]
  • [ 146579-19-3 ]
  • C21H25ClN6O5 [ No CAS ]
Reference： [1]ACS Combinatorial Science,2019,vol. 21,p. 628 - 634

Tags: 87394-65-8 synthesis path| 87394-65-8 SDS| 87394-65-8 COA| 87394-65-8 purity| 87394-65-8 application| 87394-65-8 NMR| 87394-65-8 COA| 87394-65-8 structure

Same Skeleton Products
Related Products
Historical Records

Related Functional Groups of
[ 87394-65-8 ]

Chlorides

Chemical Structure| 85386-86-3

[ 85386-86-3 ]

1-(3-Chloropyridin-2-yl)piperazine hydrochloride

Similarity: 0.93

Chemical Structure| 87394-57-8

[ 87394-57-8 ]

1-(3-Chloropyridin-2-yl)-4-methylpiperazine

Similarity: 0.93

Chemical Structure| 1280786-84-6

[ 1280786-84-6 ]

1-(3-Chloropyridin-2-yl)-4-ethylpiperazine

Similarity: 0.93

Chemical Structure| 87394-55-6

[ 87394-55-6 ]

1-(3-Chloro-2-pyridyl)piperazine

Similarity: 0.93

Chemical Structure| 1193389-39-7

[ 1193389-39-7 ]

1-(3-Chloropyridin-2-yl)piperazine dihydrochloride

Similarity: 0.93

Related Parent Nucleus of
[ 87394-65-8 ]

Pyridines

Chemical Structure| 85386-86-3

[ 85386-86-3 ]

1-(3-Chloropyridin-2-yl)piperazine hydrochloride

Similarity: 0.93

Chemical Structure| 87394-57-8

[ 87394-57-8 ]

1-(3-Chloropyridin-2-yl)-4-methylpiperazine

Similarity: 0.93

Chemical Structure| 1280786-84-6

[ 1280786-84-6 ]

1-(3-Chloropyridin-2-yl)-4-ethylpiperazine

Similarity: 0.93

Chemical Structure| 87394-55-6

[ 87394-55-6 ]

1-(3-Chloro-2-pyridyl)piperazine

Similarity: 0.93

Chemical Structure| 1193389-39-7

[ 1193389-39-7 ]

1-(3-Chloropyridin-2-yl)piperazine dihydrochloride

Similarity: 0.93

Piperazines

Chemical Structure| 85386-86-3

[ 85386-86-3 ]

1-(3-Chloropyridin-2-yl)piperazine hydrochloride

Similarity: 0.93

Chemical Structure| 87394-57-8

[ 87394-57-8 ]

1-(3-Chloropyridin-2-yl)-4-methylpiperazine

Similarity: 0.93

Chemical Structure| 1280786-84-6

[ 1280786-84-6 ]

1-(3-Chloropyridin-2-yl)-4-ethylpiperazine

Similarity: 0.93

Chemical Structure| 87394-55-6

[ 87394-55-6 ]

1-(3-Chloro-2-pyridyl)piperazine

Similarity: 0.93

Chemical Structure| 1193389-39-7

[ 1193389-39-7 ]

1-(3-Chloropyridin-2-yl)piperazine dihydrochloride

Similarity: 0.93